CVS Health Corp (NYSE: $CVS ) Walgreens Boots Alliance Inc. (NASDAQ: $WBA ) Rite Aid Corporation (NYSE: $RAD ) Stop Heartburn Drug Sales Over Cancer Links

Sector Reports > Latest News > ASX > CVS Health Corp (NYSE: $CVS ) Walgreens Boots Alliance Inc. (NASDAQ: $WBA ) Rite Aid Corporation (NYSE: $RAD ) Stop Heartburn Drug Sales Over Cancer Links

Sector Reports are pleased to announce our coverage on the below stocks.

For daily updates, news, trade ideas and complimentary research reports please insert your email in the box below and get instant access to our latest research reports, which include Cannabis, AI, Gold, Gambling and more.

CVS Health Corp (NYSE: CVS), Walgreens Boots Alliance Inc. (NASDAQ: WBA) and Rite Aid Corporation (NYSE: RAD) had mixed fortunes in the market. This is after announcing they will no longer sell a heartburn medication suspected of containing a cancer-causing substance. Zantac is the heartburn medication on the spotlight on the Food and Drug Administration, raising the red flag.

Enter Your Email for Instant Access to the Best Free ASX Research on the Markets

Zantac Cancer Links

The FDA in a press release has warned that the drug could contain low levels of nitrosamine, an impurity categorized as a human carcinogen. CVS Health stock was up 1.59% while Walgreens stock rallied 1.65% and Rite Aid plunged 4.53% after announcing the withdrawal of Zantac from shelves.

Rite Aid has confirmed it is in the process of removing the drug from its shelves as well as other generic version sold under its brand name. Walgreens and CVS have since confirmed that customers would purchase Zantac can return the medication for a refund. However, the companies insist the FDA has not recalled the drug.

Novartis AG (NYSE: NVS) is another pharmaceutical company dragged into the ranitidine standoff. The company has also stopped selling a prescription form of ranitidine as it awaits the FDA’s ongoing investigation. GlaxoSmithKline plc. (NYSE: GSK) has also stopped the distribution of a generic version of the drug

Sanofi SA (NASDAQ: SNY), which is the company behind Zantac, was up 0.15% even as the giant pharmaceutical companies announced they would no longer sell the drug. The drugmaker, in its defense, maintains that the levels of contaminants found by the FDA barely exceed the levels found in foods.

The environmental contaminant is mostly found in water and foods as well as meats and dairy products. In high levels, the contaminant can trigger tumors in the liver as well as other organs. In humans, they can lead to cancer.

FDA Ranitidine And Zantac Probe

The FDA is currently investigating a number of ranitidine drugs as well as Zantac on concerns that they contain high levels of nitrosamine impurity that can trigger cancer cells in the human body. The agency is also investigating the possible cause of contamination as well as the potential risk of the impurity to patients.

However, the agency is yet to issue an order prohibiting the sale of Zantac drug. Sales suspension by the pharmaceutical giants is thus a precautionary measure awaiting the outcome of the ongoing trials by the agency.

“The FDA is not calling for individuals to stop taking ranitidine at this time; however, patients taking prescription ranitidine who wish to discontinue use should talk to their health care professional about other treatment options,” FDA in a statement.

Instead of taking Zantac and other OTC ranitidine, the FDC is urging people to take other OTC approved medicines for their conditions.

The European Medicines Agency has already joined the FDA in reviewing the drug. Canada, on its part, has stopped the sale of all ranitidine drugs awaiting the ongoing investigations.

Enter Your Email for Instant Access to the Best Free ASX Research on the Markets



This website is a service of Profectus Solutions Pty. Ltd. an investor relations group and media firm. The website or article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Profectus is not responsible for material posted on this website and does not guarantee the content, accuracy, or use of the content in this site. No advice or information, whether oral or written, obtained by you from Profectus Solutions or through or from the service shall create any warranty not expressly stated.

Profectus Solutions do not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Profectus does not in any way endorse or recommend individuals, products or services that may be discussed on this site. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional licensed financial planner and adviser. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Conflict of interest

Directors, staff or third parties of Profectus may at times own shares of companies that are profiled within our network. We as part of our business model actively seek to do business with listed ASX or other companies.

We have NOT been compensated for the production of this webpage.

Leave a Reply

Your email address will not be published.